Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

triple antiemetic drugs

PreclinicalSmall molecule

ZZhejiang University

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

PONVRecruiting

PONVPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2027

PONV

NCT07480785

Clinical

Trials by Indication[1]

PONV1 trial

TEAS Combined With Triple Antiemetic Drugs to Prevent PONV in High-Risk Patients

Recruiting·ZZhejiang University·N/A·NCT07480785·780 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for triple antiemetic drugs. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — triple antiemetic drugs compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for triple antiemetic drugs. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: ZZhejiang University

Related News